by Madaline Spencer | Dec 18, 2025
Lisa Abbott, MD, endocrinologist with Northern Nevada Endocrinology, discusses the expansion of broader dosing ranges of Skytrofa (lonapegsomatropin) now available for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD). ...
by Madaline Spencer | Dec 17, 2025
The U.S. Food and Drug Administration (FDA) has approved Uplizna (inebilizumab) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) and anti-muscle specific tyrosine kinase (MuSK) antibody positive. gMG is a...
by Madaline Spencer | Dec 17, 2025
A recent study, published in the New England Journal of Medicine, looked at the effects of sotatercept for pulmonary arterial hypertension (PAH) within the first year after diagnosis. PAH affects the heart and lungs. It is characterized by abnormally high blood...
by Madaline Spencer | Dec 16, 2025
The U.S. Food and Drug Administration (FDA) has approved an oral pellet formulation of Orladeyo (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) ages 2 to less than 12 years of age. HAE is a condition characterized by...
by Madaline Spencer | Dec 16, 2025
Michael Manning, MD, Allergist and Immunologist, discusses long-term data with Dawnzera (donidalorsen) for the treatment of patients with hereditary angioedema (HAE). HAE is a condition where people have recurrent episodes of severe swelling of the skin...
